Which one is preferable in NGS? Using different software for secondary and tertiary analyses or using one complete software package for both of the above? Waiting for some lights to be thrown of.............
-
-
software
There is no such thing that one tool/ software for all your needs. I have seen people doing mistakes. It will depend on what your questions are e.g in Chip seq histone modification and transcription factor are two different kinds of analysis though basic concept is similar (in layman- no of reads in a particular region) -
Hey Honey.. Thnx for your getting back on this.. I put the question from a different point of view..You have two options to go for:
1. You have a suite/ soft package which performs all basic analyses before going downstream, say, de novo assembly or reference guided alignment etc and also doing all those downstream analyses you are concern about (as you said, ChIP, gene expression analysis) in a interoperable manner.
2. You have to use a software for performing assembly, alignment etc and a different software for your concerned downstream experiment.
So, which one you would go for? A soft package or different soft?
So far I think, there may be some compatibility issues between output of a software and input of next required software, which have to be solved by some conversion tool.
Don't you think here researchers may face some troble in converting the formats?Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...Yesterday, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM
Comment